Peter Gordon Middleton

List of Publications by Year
in descending order

60 papers	5,763 citations	147801 31 h-index	133252 59 g-index
60 all docs	60 docs citations	60 times ranked	5187 citing authors

#	Article	IF	Citations
1	Transition to adult care in cystic fibrosis: The challenges and the structure. Paediatric Respiratory Reviews, 2022, 41, 23-29.	1.8	5
2	Factors associated with clinical progression to severe COVID-19 in people with cystic fibrosis: A global observational study. Journal of Cystic Fibrosis, 2022, 21, e221-e231.	0.7	15
3	Redesign of the Australian Cystic Fibrosis Data Registry: A multidisciplinary collaboration. Paediatric Respiratory Reviews, 2021, 37, 37-43.	1.8	3
4	Azithromycin and tezacaftor/ivacaftor is associated with first-degree heart block in an adult with cystic fibrosis. Journal of Cystic Fibrosis, 2021, 20, e19-e21.	0.7	4
5	Development of elexacaftor â€“ tezacaftor â€“ ivacaftor: Highly effective CFTR modulation for the majority of people with Cystic Fibrosis. Expert Review of Respiratory Medicine, 2021, 15, 723-735.	2.5	23
6	Avatar acceptability: views from the Australian Cystic Fibrosis community on the use of personalised organoid technology to guide treatment decisions. ERJ Open Research, 2021, 7, 00448-2020.	2.6	7
7	Concerns regarding the safety of azithromycin in pregnancy - relevance for women with cystic fibrosis. Journal of Cystic Fibrosis, 2021, 20, 395-396.	0.7	9
8	Long-term safety and efficacy of tezacaftorâ€“ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study. Lancet Respiratory Medicine,the, 2021, 9, 733-746.	10.7	33
9	Pregnancy in women with Cystic Fibrosis in the 21st century. Journal of Cystic Fibrosis, 2021, 20, 375-376.	0.7	2
10	COVID-19 vaccine prioritisation for people with cystic fibrosis. Journal of Cystic Fibrosis, 2021, 20, 715-716.	0.7	5
11	Triple Therapy for Cystic Fibrosis Phe508delâ€“Gating and â€“Residual Function Genotypes. New England Journal of Medicine, 2021, 385, 815-825.	27.0	140
12	Family planning, pregnancy and birth in women with lung conditions: a worldwide survey. ERJ Open Research, 2021, 7, 00357-2021.	2.6	2
13	Distal intestinal obstruction syndrome: an important differential diagnosis for abdominal pain in patients with cystic fibrosis. ANZ Journal of Surgery, 2020, 90, 681-686.	0.7	8
14	The global impact of SARS-CoV-2 in 181 people with cystic fibrosis. Journal of Cystic Fibrosis, 2020, 19, 868-871.	0.7	74
15	A multinational report to characterise SARS-CoV-2 infection in people with cystic fibrosis. Journal of Cystic Fibrosis, 2020, 19, 355-358.	0.7	113
16	Outcomes of pregnancy in women with cystic fibrosis (CF) taking CFTR modulators â€“ an international survey. Journal of Cystic Fibrosis, 2020, 19, 521-526.	0.7	57
17	ERS/TSANZ Task Force Statement on the management of reproduction and pregnancy in women with airways diseases. European Respiratory Journal, 2020, 55, 1901208.	6.7	75
18	Australian adults with bronchiectasis: The first report from the Australian Bronchiectasis Registry. Respiratory Medicine, 2019, 155, 97-103.	2.9	48

#	Article	IF	Citations
19	Elexacaftorâ€“Tezacaftorâ€“Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele. New England Journal of Medicine, 2019, 381, 1809-1819.	27.0	1,231
20	Management of Australian Adults with Bronchiectasis in Tertiary Care: Evidence-Based or Access-Driven?. Lung, 2019, 197, 803-810.	3.3	14
21	Long-Term CFTR Modulators and Changes in Hemoglobin. Annals of the American Thoracic Society, 2019, 16, 305-306.	3.2	0
22	Intermittent colonisation with Methicillin-Resistant Staphylococcal aureus can be eradicated from the Airways of Adults with Cystic Fibrosis. Antibiotics, 2019, 8, 113.	3.7	1
23	CFTR activity is enhanced by the novel corrector GLPG2222, given with and without ivacaftor in two randomized trials. Journal of Cystic Fibrosis, 2019, 18, 700-707.	0.7	38
24	Trial Refresh: A Case for an Adaptive Platform Trial for Pulmonary Exacerbations of Cystic Fibrosis. Frontiers in Pharmacology, 2019, 10, 301.	3.5	7
25	Treatable traits can be identified in a severe asthma registry and predict future exacerbations. Respirology, 2019, 24, 37-47.	2.3	136
26	Working while unwell: Workplace impairment in people with severe asthma. Clinical and Experimental Allergy, 2018, 48, 650-662.	2.9	57
27	Pseudomonas aeruginosa Inhibits the Growth of Scedosporium and Lomentospora In Vitro. Mycopathologia, 2018, 183, 251-261.	3.1	32
28	Work environment risks for health care workers with cystic fibrosis. Respirology, 2018, 23, 1190-1197.	2.3	7
29	Methicillinâ€resistant <scp>Staphylococcus aureus</scp> in healthâ€care workers with cystic fibrosis in Sydney. Respirology Case Reports, 2018, 6, e00378.	0.6	1
30	Does newborn screening influence the young cystic fibrosis cohort included in national registries?. European Respiratory Journal, 2017, 49, 1600686.	6.7	3
31	A randomised trial of hypertonic saline during hospitalisation for exacerbation of cystic fibrosis. Thorax, 2016, 71, 141-147.	5.6	40
32	Lumacaftorâ€“Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508delCFTR. New England Journal of Medicine, 2015, 373, 220-231.	27.0	1,308
33	Nasal potential difference measurements in diagnosis of cystic fibrosis: An international survey. Journal of Cystic Fibrosis, 2014, 13, 24-28.	0.7	34
34	Australian standards of care for cystic fibrosisâ€related diabetes. Respirology, 2014, 19, 185-192.	2.3	32
35	Cystic Fibrosis Related Diabetes: Potential pitfalls in the transition from paediatric to adult care. Paediatric Respiratory Reviews, 2014, 15, 281-284.	1.8	3
36	Validation of the Sonomat: A Contactless Monitoring System Used for the Diagnosis of Sleep Disordered Breathing. Sleep, 2014, 37, 1477-1487.	1.1	62

#	Article	IF	Citations
37	CFTR biomarkers: time for promotion to surrogate end-point. European Respiratory Journal, 2013, 41, 203-216.	6.7	93
38	Fungal infections and treatment in cystic fibrosis. Current Opinion in Pulmonary Medicine, 2013, 19, 670-675.	2.6	38
39	Influence of perfusate temperature on nasal potential difference. European Respiratory Journal, 2013, 42, 389-393.	6.7	7
40	Long term effects of denufosol tetrasodium in patients with cystic fibrosis. Journal of Cystic Fibrosis, 2012, 11, 539-549.	0.7	85
41	Timing of dornase alpha inhalation does not affect the efficacy of an airway clearance regimen in adults with cystic fibrosis: a randomised crossover trial. Journal of Physiotherapy, 2011, 57, 223-229.	1.7	14
42	Development and Validation of a Multiplex PCR for Detection of Scedosporium spp. in Respiratory Tract Specimens from Patients with Cystic Fibrosis. Journal of Clinical Microbiology, 2011, 49, 1508-1512.	3.9	39
43	Measurement of airway ion transport assists the diagnosis of cystic fibrosis. Pediatric Pulmonology, 2010, 45, 789-795.	2.0	15
44	Clinical associations and prevalence ofScedosporiumspp. in Australian cystic fibrosis patients: identification of novel risk factors?. Medical Mycology, 2010, 48, S37-S44.	0.7	93
45	Detection of Occult Scedosporium Species in Respiratory Tract Specimens from Patients with Cystic Fibrosis by Use of Selective Media. Journal of Clinical Microbiology, 2010, 48, 314-316.	3.9	74
46	Randomized Trial of a Decision Aid for Patients with Cystic Fibrosis Considering Lung Transplantation. American Journal of Respiratory and Critical Care Medicine, 2009, 180, 761-768.	5.6	57
47	Phenotypic characterisation of patients with intermediate sweat chloride values: towards validation of the European diagnostic algorithm for cystic fibrosis. Thorax, 2009, 64, 683-691.	5.6	63
48	Impact of different chloride and glucose solutions on nasal potential difference. Pediatric Pulmonology, 2009, 44, 645-648.	2.0	5
49	Cystic fibrosis infections: treatment strategies and prospects. FEMS Microbiology Letters, 2009, 300, 153-164.	1.8	62
50	Treatment of obstructive sleep apnoea in Samoa progressively reduces daytime blood pressure over 6â€ƒmonths. Respirology, 2009, 14, 404-410.	2.3	12
51	In vitrointeractions of tobramycin with various nonantibiotics againstPseudomonas aeruginosaandBurkholderia cenocepacia. FEMS Microbiology Letters, 2008, 285, 40-50.	1.8	11
52	Editorial overview: Clinical utility of synergy testing for multidrug resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis. Paediatric Respiratory Reviews, 2007, 8, 262-264.	1.8	2
53	Combination aerosol therapy to treat Burkholderia cepacia complex. European Respiratory Journal, 2005, 26, 305-308.	6.7	35
54	Airway Surface Liquid Calcium Modulates Chloride Permeability in the Cystic Fibrosis Airway. American Journal of Respiratory and Critical Care Medicine, 2003, 168, 1223-1226.	5.6	9

#	Article	IF	Citations
55	Sleep disordered breathing and pregnancy. Thorax, 2002, 57, 555-558.	5.6	104
56	Hypertonic saline alters ion transport across the human airway epithelium. European Respiratory Journal, 2001, 17, 195-199.	6.7	18
57	The In Vivo Effects of Milrinone on the Airways of Cystic Fibrosis Mice and Human Subjects. American Journal of Respiratory Cell and Molecular Biology, 1999, 20, 129-134.	2.9	54
58	Liposome-mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. Nature Medicine, 1995, 1, 39-46.	30.7	736
59	Nonâ€“invasive liposomeâ€“mediated gene delivery can correct the ion transport defect in cystic fibrosis mutant mice. Nature Genetics, 1993, 5, 135-142.	21.4	425
60	Nasal epithelial ion transport and genetic analysis of infertile men with congenital bilateral absence of the vas deferens. Human Molecular Genetics, 1993, 2, 1605-1609.	2.9	83